AUROPHARMA · Health Care · 2026-08-21

Aurobindo Pharma Ltd

7.0★★ GoodStrong +6.1Stage 2 · wk 23In scan: Breakout WatchMARKET: BULL RISING · 2026-08-21
₹1,621.3
+0.83% today
₹93,286 Cr · Large cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.

Visit company website →
P/E (TTM)
23.8
Forward 16.2
Earnings Growth (YoY)
+1.9%
Revenue +5.6%
ROE
+9.9%
Profit margin +10.4%
Dividend Yield
0.27%
P/B 2.2
vs 52W High
-2.7%
₹1,022.2 lo₹1,667 hi
2.7% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 23
1w13w26w
Week 23 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
20.3%
200 DMA: ₹1,347.3 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.62x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
MA20 gently rising · +2.9% vs MA50 +3.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
55.5%
20d Δ
+3.9pp
1M return
+2.7%
3M return
+9.6%
Sector Stage-2 % · last 20 days
This stock ranks #19 of 84 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
56.1%
20d Δ
+5.6pp
1M return
+2.7%
3M return
+10.4%
Industry Stage-2 % · last 20 days
Ranks #16 of 58 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-05-26 → 2026-08-21
S2 43w
S2 27w
S4 18w
S4 18w
S2 23w
2023-05-262026-08-21
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 43w → S3 6w → S2 27w → S3 8w → S4 18w → S1 8w → S4 18w → S1 3w → S2 11w → S3 4w → S2 23w current
Total tracked: 169 weeks across 11 stage runs.
1M
+6.4%
3M
+10.8%
6M
+36.9%
YTD
+34.4%
1Y
+53.2%
Scan Membership
Breakout Watch
Latest: 2026-03-13
3 appearances in last 60 days. First seen: 2024-04-29.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-21S2
Wk 23 · Vol —x
2026-08-20S2
Wk 22 · Vol —x
2026-08-19S2
Wk 22 · Vol —x
2026-08-18S2
Wk 22 · Vol —x
2026-08-17S2
Wk 22 · Vol —x
2026-08-14S2
Wk 22 · Vol —x
2026-08-13S2
Wk 21 · Vol —x
2026-08-12S2
Wk 21 · Vol —x
2026-08-11S2
Wk 21 · Vol —x
2026-08-10S2
Wk 21 · Vol —x
2026-08-07S2
Wk 21 · Vol —x
2026-08-06S2
Wk 20 · Vol —x
Sector Peers — Stage 2All →
NEULANDLAB
wk 12 · -1.5% from hi
9.0
ALIVUS
wk 19 · -3.4% from hi
9.0
DIVISLAB
wk 14 · -0.0% from hi
8.8
SAILIFE
wk 25 · -1.0% from hi
8.8
SHILPAMED
wk 15 · -0.9% from hi
8.6
Moving averages & range
50 DMA
₹1,563.9
200 DMA
₹1,347.3
52W High
₹1,667
52W Low
₹1,022.2
5D Low
₹1,608
Resistance levels (recent highs)
20d High
₹1,667
60d High
₹1,667
120d High
₹1,667
250d High
₹1,667
Next resistance
+2.8%
to 20d High

All analytics based on EOD data. Data as of 2026-08-21. Past data patterns are not indicative of future results. This page is a data analytics tool only.